Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.55 |
| ▸ | CDK4 | P11802 | 4/20 | 0.50 |
| ▸ | CCND1 | P24385 | 4/20 | 0.50 |
| ▸ | PLAU | P00749 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30218821 | 0.84 | HTR6 (0.55) | HTR6CDK4CCND1PLAUKMT2A | |
| SCHEMBL6086304 | 0.84 | HTR6 (0.55) | HTR6CDK4CCND1PLAUKMT2A | |
| SCHEMBL29509279 | 0.81 | HTR6 (0.73) | HTR6CDK4CCND1PLAUKMT2A | |
| SCHEMBL31021 | 0.81 | HTR6 (0.73) | HTR6CDK4CCND1PLAUKMT2A | |
| SCHEMBL6085311 | 0.81 | HTR6 (0.59) | HTR6CDK4CCND1PLAUKMT2A | |
| SCHEMBL8386546 | 0.81 | HTR6 (0.55) | HTR6CDK4CCND1PLAUKMT2A | |
| SCHEMBL30218818 | 0.81 | HTR6 (0.59) | HTR6CDK4CCND1PLAUKMT2A | |
| SCHEMBL1104768 | 0.81 | HTR6 (0.55) | HTR6CDK4CCND1PLAUKMT2A | |
| SCHEMBL31258087 | 0.81 | HTR6 (0.55) | HTR6CDK4CCND1PLAUKMT2A | |
| SCHEMBL2047825 | 0.81 | HTR6 (0.69) | HTR6CDK4CCND1PLAUKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054629-A1 | Compounds and methods of treating cell proliferative diseases | EXONHIT THERAPEUTICS SA (FR) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054629-A1 | Compounds and methods of treating cell proliferative diseases | MKI67, CCNC, PCNA | HTR6 2401/4885CDK4 7/4885CCND1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.